NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals declared that its board has approved a share repurchase plan on Tuesday, November 5th 2019, which allows the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 2.9% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board believes its stock is undervalued.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) issued its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported $6.67 EPS for the quarter, beating analysts' consensus estimates of $5.13 by $1.54. The biopharmaceutical company earned $2.05 billion during the quarter, compared to analysts' expectations of $1.98 billion. Regeneron Pharmaceuticals had a return on equity of 24.85% and a net margin of 28.13%. The company's quarterly revenue was up 23.2% on a year-over-year basis. During the same period last year, the business posted $5.87 EPS. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

20 equities research analysts have issued twelve-month price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $320.00 to $453.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $391.78 in the next year. This suggests a possible upside of 13.5% from the stock's current price. View Analyst Price Targets for Regeneron Pharmaceuticals.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regeneron Pharmaceuticals.

Media stories about REGN stock have trended extremely negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a news impact score of -4.5 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Regeneron Pharmaceuticals.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Gilead Sciences (GILD), Celgene (CELG), Biogen (biib), Alibaba Group (BABA), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Amgen (AMGN) and Broadcom (AVGO).

Regeneron Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.37%), New York State Teachers Retirement System (0.10%), Hexavest Inc. (0.08%), DNB Asset Management AS (0.06%), Nippon Life Global Investors Americas Inc. (0.05%) and Wealthstreet Investment Advisors LLC (0.04%). Company insiders that own Regeneron Pharmaceuticals stock include Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Rhenman & Partners Asset Management AB, OLD National Bancorp IN, Assenagon Asset Management S.A., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Strs Ohio, Hexavest Inc. and State of Alaska Department of Revenue. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

REGN stock was acquired by a variety of institutional investors in the last quarter, including First National Bank of Omaha, DNB Asset Management AS, Cardinal Capital Management, Nisa Investment Advisors LLC, Nippon Life Global Investors Americas Inc., Janney Montgomery Scott LLC, Exane Derivatives and Advisors Preferred LLC. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $345.28.

Regeneron Pharmaceuticals has a market capitalization of $37.91 billion and generates $6.71 billion in revenue each year. The biopharmaceutical company earns $2.44 billion in net income (profit) each year or $19.80 on an earnings per share basis. Regeneron Pharmaceuticals employs 7,400 workers across the globe.View Additional Information About Regeneron Pharmaceuticals.

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]